双相障碍与重性抑郁障碍中代谢型谷氨酸受体5定量差异
该研究首次使用[18F]FPEB正电子发射断层成像测量重性抑郁障碍(MDD)与双相障碍(BD)患者前额叶皮层代谢型谷氨酸受体5(mGluR5)可用性。结果显示BD组mGluR5可用性显著低于MDD和健康对照组,MDD与健康对照组无差异;MDD中较低背外侧前额叶mGluR5与更重抑郁症状相关,MDD和BD抑郁组mGluR5与工作记忆呈负相关。
要点
- BD患者前额叶皮层mGluR5可用性低于MDD和健康对照,MDD与健康对照无差异。
- MDD中较低背外侧前额叶mGluR5与更重抑郁症状相关(r=-0.67,p=.005),BD中无此关联。
- MDD和BD抑郁组中mGluR5与工作记忆呈显著负相关。
核心结论
- mGluR5可能有助于区分BD与MDD,并作为MDD抑郁症状及两病认知改变的潜在治疗靶点。
研究设计与样本
- 横断面正电子发射断层成像研究,使用[18F]FPEB量化前额叶皮层mGluR5可用性。
- 样本包括BD抑郁17例、BD缓解10例、MDD 17例和健康对照18例。
主要发现
- 前额叶皮层mGluR5可用性组间差异显著(F6,116=2.18,p=.050)。
- BD组mGluR5低于MDD和健康对照组,MDD与健康对照组无差异。
- BD抑郁和BD缓解亚组mGluR5均低于MDD和健康对照组。
- MDD中较低背外侧前额叶mGluR5与更重抑郁相关(r=-0.67,p=.005),BD中无此关联。
- MDD和BD抑郁组中mGluR5与工作记忆呈显著负相关。
临床怎么用
- mGluR5成像可能辅助鉴别BD与MDD,但尚需进一步验证。
- 针对mGluR5的干预可能改善MDD抑郁症状及两病认知损害,目前仍属研究阶段。
局限性
- 样本量较小,需进一步研究确认mGluR5在BD与MDD中的区分作用。
- 需进一步探究mGluR5调控作为预防/治疗策略的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the neurobiology underlying bipolar disorder (BD) versus major depressive disorder (MDD) is crucial for accurate diagnosis and for driving the discovery of novel treatments. A promising target is the metabotropic glutamate receptor 5 (mGluR5), a modulator of glutamate transmission associated with synaptic plasticity. We measured mGluR5 availability in individuals with MDD and BD for the first time using positron emission tomography. METHODS: Individuals with BD (n = 17 depressed; n = 10 euthymic) or MDD (n = 17) and healthy control (HC) individuals (n = 18) underwent imaging with [18F]FPEB positron emission tomography to quantify mGluR5 availability in regions of the prefrontal cortex, which was compared across groups and assessed in relation to depressive symptoms and cognitive function. RESULTS: Prefrontal cortex mGluR5 availability was significantly different across groups (F6,116 = 2.18, p = .050). Specifically, mGluR5 was lower in BD versus MDD and HC groups, with no difference between MDD and HC groups. Furthermore, after dividing the BD group, mGluR5 was lower in both BD-depression and BD-euthymia groups versus both MDD and HC groups across regions of interest. Interestingly, lower dorsolateral prefrontal cortex mGluR5 was associated with worse depression in MDD (r = -0.67, p = .005) but not in BD. Significant negative correlations were observed between mGluR5 and working memory in MDD and BD-depression groups. CONCLUSIONS: This work suggests that mGluR5 could be helpful in distinguishing BD and MDD as a possible treatment target for depressive symptoms in MDD and for cognitive alterations in both disorders. Further work is needed to confirm differentiating roles for mGluR5 in BD and MDD and to probe modulation of mGluR5 as a preventive/treatment strategy.
引用
- Holmes SE, Asch RH, Davis MT, et al. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biol Psychiatry. 2022. PMID: 36764853. doi:10.1016/j.biopsych.2022.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。